一位患有慢性心臟衰竭的病人正在服用 Spironolactone。哪項實驗室數值需要護理師立即採取後續行動？

Spironolactone 是一種保鉀利尿劑（Aldosterone antagonist），其作用機轉是在遠曲小管抑制鈉的重吸收並保留鉀離子。對於心衰竭病人，雖然此藥能改善預後，但最嚴重的風險是導致高血鉀。血鉀的正常範圍為 3.5-5.0 mEq/L，當數值達到 5.6 mEq/L 時屬於高血鉀，這會顯著增加致命性心律不整的風險（如室性心搏過速或心臟停止）。護理師必須立即辨識此一藥物副作用。相較之下，血鈉、肌酸酐與血糖在此案例中均處於正常或接近正常範圍，不具備立即的威脅性。臨床決策中，藥物安全性監測（Medication Safety Monitoring）是減少病人風險的核心，特別是針對具有狹窄治療指數或已知嚴重電解質副作用的藥物。

Spironolactone is a potassium-sparing diuretic (an aldosterone antagonist) whose mechanism is to inhibit sodium reabsorption in the distal tubule while retaining potassium. Although this medication can improve outcomes in patients with heart failure, its most serious risk is causing hyperkalemia. The normal range for serum potassium is 3.5 to 5.0 mEq/L; a value of 5.6 mEq/L represents hyperkalemia, which significantly increases the risk of life-threatening cardiac arrhythmias (such as ventricular tachycardia or cardiac arrest). The nurse must recognize this adverse effect immediately. In contrast, the sodium, creatinine, and glucose values in this case are all within or near normal range and do not pose an immediate threat. In clinical decision-making, medication safety monitoring is central to reducing patient risk, especially with drugs that have a narrow therapeutic index or known serious electrolyte adverse effects.

美國護理實務中，對於高血鉀的警覺性極高，且藥師常參與用藥監測；台灣臨床護理師則需密切注意檢驗系統的「危險值」通報，並在交班時特別強調此數值，以免醫師忽略慢性調整藥物的必要性。